Francais

Summary

Drug resistance and new cancer treatments (DRCT)

Team Leader  : Céline Gongora
 
Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle
34298 Montpellier cedex 5

 
Tél. : 33 (0)4 67 61 37 45
Fax : 33 (0)4 67 61 37 87
celine.gongora@inserm.fr
 
Research topics
 

One of the main causes of failure in cancer treatment is the development of drug resistance by cancer cells. In the past decades, new drugs (particularly the so-called targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors and immune checkpoint inhibitors) have been developed to bypass therapeutic failure in cancer treatment. However, the assessment of these targeted therapies, either alone or in combination with standard cytotoxic agents, in clinical trials shows that, although some are efficient and have been subsequently approved for routine clinical use, many of them are not. Indeed, most solid tumors display huge genomic complexity and therefore multiple pathways or networks need to be targeted to affect tumor survival. Furthermore, the assessment of the efficacy of a new drug can be complicated by inter- and intra-patient pharmacokinetic variations that can result in unpredictable toxicity and variable anticancer effects.

The research project of this group focus on optimizing drug therapy in solid tumor models. The main axes of our research project are: a) the identification of innovative targets, b) the development of treatments to overcome drug resistance, c) the comprehension of drug responses and d) the identification of biomarkers of cancer development and drug resistance. 

 

 

 

more information ...

 

 
Recent Publications

 

Mbatchi LC, Gassiot M, Pourquier P, Goberna A, Mahammedi H, Mourey L, Joly F, Lumbroso S, Evrard A, Houede N. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Jul 4. doi: 10.1007/s00280- 017-3379-5. [Epub ahead of print]

 

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046 -017-0558-5.

 

Joffre C, Djavaheri-Mergny M, Pattingre S, Giuriato S. The yin and the yang of autophagy in cancer cells. Med Sci (Paris). 2017 Mar;33(3):328-334. doi: 10.1051 /medsci/20173303021.

 

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017 Mar 8;76:68-75. doi: 10.1016/j.ejca.2017.02.003. [Epub ahead of print]

 

Lehmann-Che J, Poirot B, Boyer JC, Evrard A. La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision. Therapie. 2017 Jan 3. pii: S0040-5957(16)31284-7. doi: 10.1016/j.therap.2016.09.009. [Epub ahead of print]


more information ...

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Sign in - Conception : ID Alizés